Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Europe's HAE Market Big Enough To Sustain All The Competitors?

Executive Summary

As more companies of all sizes embrace rare diseases – lured in part by supposed lower regulatory and reimbursement hurdles – some niche markets are beginning to look rather busy.
Advertisement

Related Content

The First Shall Be Fifth: Salix’s Recombinant C1 Esterase Inhibitor Enters Crowded HAE Market
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
Shire To Test Convenience Versus Familiarity In HAE Space With Approval Of Firazyr
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Shire Finally Able To Move Firazyr Forward

Topics

Advertisement
UsernamePublicRestriction

Register

PS053231

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel